WST

West Pharmaceutical Services Inc

Add to Watchlist

Advanced Chart

275.340

-8.2(-2.892%)1D

Line

Candle

YTD

High

285.550

Open

282.040

VWAP

275.51

Vol

1.04M

Mkt Cap

19.81B

Low

262.4842

Amount

286.07M

EV/EBITDA(TTM)

24.99

Total Shares

72.84M

19.98B

EV/OCF(TTM)

28.80

P/S(TTM)

6.85

West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

814.21M

+6.22%

1.947

+5.79%

759.75M

+8.85%

1.641

+13.2%

795.82M

+6.28%

1.839

+1.06%

Estimates Revision

The market is revising Upward the revenue expectations for West Pharmaceutical Services, Inc. (WST) for FY2025, with the revenue forecasts being adjusted by 0.45% over the past three months. During the same period, the stock price has changed by 16.04%.

Revenue Estimates for FY2025

Revise Upward

+0.45%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.97%

In Past 3 Month

Stock Price

Go Up

+16.04%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 347.63 USD with a low forecast of 311.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 275.340

Low

311.00

Averages

347.63

High

375.00

Current: 275.340

Low

311.00

Averages

347.63

High

375.00

TD Cowen

Brendan Smith

Buy

initiated

$350

2025-10-29

Reason

TD Cowen

Brendan Smith

Price Target

$350

2025-10-29

initiated

Buy

Reason

TD Cowen analyst Brendan Smith initiated coverage of West Pharmaceutical with a Buy rating and $350 price target. West sits at the nexus of multiple, sector-wide trends - including injectable biologics, GLP-1s and expanding regulatory demand - that have helped the company evolve from a supplier of standard drug delivery components towards high-value products with higher gross margins, the analyst tells investors. The mix shift to higher value products should sustainably grow revenue and margins long term, the analyst contends.

Barclays

Equal Weight

maintain

$275 -> $325

2025-10-27

Reason

Barclays

Price Target

$275 -> $325

2025-10-27

maintain

Equal Weight

Reason

Barclays raised the firm's price target on West Pharmaceutical to $325 from $275 and keeps an Equal Weight rating on the shares. The company reported a "solid beat across the board" and has a good setup into 2026, the analyst tells investors in a research note.

Evercore ISI

Daniel Markowitz

Tactical Outperform -> Outperform

downgrade

$390

2025-10-27

Reason

Evercore ISI

Daniel Markowitz

Price Target

$390

2025-10-27

downgrade

Tactical Outperform -> Outperform

Reason

Evercore ISI analyst Daniel Markowitz had a "Tactical Outperform" call on West Pharmaceutical heading into earnings, but is removing it from the firm's TAP list given that West reported earnings late last week. The firm has an Outperform rating and $390 price target on the shares.

UBS

Dan Leonard

Buy

maintain

$320 -> $355

2025-10-24

Reason

UBS

Dan Leonard

Price Target

$320 -> $355

2025-10-24

maintain

Buy

Reason

UBS analyst Dan Leonard raised the firm's price target on West Pharmaceutical to $355 from $320 and keeps a Buy rating on the shares.

BofA

Buy

upgrade

$310 -> $370

2025-10-24

Reason

BofA

Price Target

$310 -> $370

2025-10-24

upgrade

Buy

Reason

BofA raised the firm's price target on West Pharmaceutical to $370 from $310 and keeps a Buy rating on the shares after a "strong" Q3 report. The firm, which increased its EPS estimates by 5%-6%, cites growth drivers and normalizing market conditions heading into 2026 for its Buy rating.

Deutsche Bank

Justin Bowers

Buy

maintain

$305 -> $345

2025-10-24

Reason

Deutsche Bank

Justin Bowers

Price Target

$305 -> $345

2025-10-24

maintain

Buy

Reason

Deutsche Bank analyst Justin Bowers raised the firm's price target on West Pharmaceutical to $345 from $305 and keeps a Buy rating on the shares.

See All Ratings

Valuation Metrics

The current forward P/E ratio for West Pharmaceutical Services Inc (WST.N) is 37.90, compared to its 5-year average forward P/E of 42.95. For a more detailed relative valuation and DCF analysis to assess West Pharmaceutical Services Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

42.95

Current PE

37.90

Overvalued PE

50.50

Undervalued PE

35.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

28.29

Current EV/EBITDA

24.11

Overvalued EV/EBITDA

33.29

Undervalued EV/EBITDA

23.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9.65

Current PS

283.54

Overvalued PS

30.23

Undervalued PS

-10.93